Holding(s) in Company
Mark H Dixon has notified SkinBioTherapeutics PLC on October 1, 2025, that his voting rights attached to shares crossed a threshold on September 9, 2025. The notification pertains to an acquisition of voting rights. Mark H Dixon, through Rock Nominees Limited, now holds 24,887,876 ordinary shares, representing 9.617% of the voting rights in the company. There is no previous notification applicable and no voting rights through financial instruments.
Select text to share a quote on X · sign in to keep highlights & notes in your SBTX notes
Non-UK issuer
- Reason for the notification (please mark the appropriate box or boxes with an "X")
| An acquisition or disposal of voting rights | X |
An acquisition or disposal of financial instruments
An event changing the breakdown of voting rights
Other (please specify) iii :
Details of person subject to the notification obligation iv
| Name | Mark H Dixon |
City and country of registered office (if applicable)
Full name of shareholder(s) (if different from 3.) v
| Name | Rock Nominees Limited |
| City and country of registered office (if applicable) | London, UK |
| 5. Date on which the threshold was crossed or reached vi : | 9 September 2025 |
| 6. Date on which issuer notified (DD/MM/YYYY): | 1 October 2025 |
- Total positions of person(s) subject to the notification obligation
| % of voting rights attached to shares (total of 8. A) | % of voting rights through financial instruments (total of 8.B 1 + 8.B 2) | Total of both in % (8.A + 8.B) | Total number of voting rights held in issuer (8.A + 8.B) vii | |
|---|---|---|---|---|
| Resulting situation on the date on which threshold was crossed or reached | 9.617% | 9.617% | 24,887,876 | |
| Position of previous notification (if applicable) | n/a | n/a | n/a | |
| A: Voting rights attached to shares | ||||
| Class/type of shares ISIN code (if possible) | Number of voting rights ix | % of voting rights | ||
| Direct (DTR5.1) | Indirect (DTR5.2.1) | Direct (DTR5.1) | Indirect (DTR5.2.1) | |
| Ordinary shares GB00BF33H870 | 24,887,876 | 9.617% | ||
| SUBTOTAL 8. A | 24,887,876 | 9.617% | ||
| B 1: Financial Instruments according to DTR5.3.1R (1) (a) | ||||
| Type of financial instrument | Expiration date x | Exercise/ Conversion Period xi | Number of voting rights that may be acquired if the instrument is exercised/converted. | % of voting rights |
SUBTOTAL 8. B 1
B 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)
| Type of financial instrument | Expiration date x | Exercise/ Conversion Period xi | Physical or cash Settlement xii | Number of voting rights | % of voting rights |
| SUBTOTAL 8.B.2 | |||||
| Name xv | % of voting rights if it equals or is higher than the notifiable threshold | % of voting rights through financial instruments if it equals or is higher than the notifiable threshold | Total of both if it equals or is higher than the notifiable threshold | ||
| 10. In case of proxy voting, please identify: | |||||
| Name of the proxy holder | N/A | ||||
| The number and % of voting rights held | N/A | ||||
| The date until which the voting rights will be held | N/A | ||||
| 11. Additional information xvi | |||||
| Place of completion | London | ||||
| Date of completion | 1 October 2025 | ||||
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.